Gabapentin enacarbil significantly improves neuropathic pain associated with postherpetic neuralgia

Up to 3600 mg total daily doses of gabapentin enacarbil, a transported prodrug of gabapentin, significantly improves neuropathic pain associated with postherpetic neuralgia compared with placebo. So found a randomized, double-blind, parallel-group, placebo-controlled study that compared a total daily dose of gabapentin enacarbil 1200 mg, 2400 mg, or 3600 mg with placebo over 12 weeks in adults =18 years with postherpetic neuralgia for =3 months, a baseline 24-hour average pain score =4, and a creatinine clearance =60mL/min.

Originally published on MPR - Monthly Prescribing Reference.

Click here to register to receive Monthly Prescribing Reference newsletters

Primary end point was change in baseline to end of treatment in mean 24-hour average pain intensity score, as recorded daily by patients using an 11-point rating scale, where 0 was "no pain" and 10 was "pain as bad as you can imagine," reported Richard L. Rauck, MD, Carolinas Pain Institute, Winston-Salem, NC, and colleagues. Treatment-emergent adverse events (TEAEs), vital signs, laboratory assessments, and results of electrocardiograms were also recorded.

Of the 376 subjects, 107 were randomized to gabapentin enacarbil 1200 mg; 84 to gabapentin enacarbil 2400 mg, 90 to gabapentin enacarbil 3600 mg, and 95 to placebo. All doses of gabapentin enacarbil significantly reduced 24-hour average pain score: -2.48, -2.28, and -2.80, respectively, vs placebo, -1.67. The adjusted mean treatment difference vs placebo was -0.81 for gabapentin enacarbil 1200 mg (P=0.013); -0.7 for the 2400 mg dose (P=0.029); and -1.07 for the 3600 mg dose (P=0.002).

Dizziness and somnolence were the most commonly reported TEAEs; for the gabapentin enacarbil 1200 mg, 2400 mg, 3600 mg, dizziness occurred in 17%, 26%, and 30% of patients compared with 15% in the placebo group, and somnolence occurred in 10%, 11%, and 14%, respectively, vs 8% receiving placebo.

No clinically relevant changes in vital signs, laboratory assessments, or electrocardiograms were observed, the investigators concluded during The American Pain Society's 29th Annual Scientific Meeting.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus